Switzerland

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Novartis Receives FDA Approval of Xolair® (Omalizumab) Self-Injection with Prefilled Syringe Across All Indications for Appropriate Patient...

Lead Product(s): Omalizumab

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Xolair

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 12, 2021

Details:

Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada

Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair Breezhaler

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Valeo Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 29, 2021

Details:

Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair® Breezhaler® and Atectura® Breezhaler® for an initial 8 year period.